Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.

[1]  S. Christensen,et al.  1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. , 1998, Journal of medicinal chemistry.

[2]  S. Christensen,et al.  SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. , 1998, The Journal of pharmacology and experimental therapeutics.

[3]  A. Kagey‐Sobotka,et al.  Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. , 1997, The Journal of pharmacology and experimental therapeutics.

[4]  C. Houghton,et al.  Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin‐2 release from murine splenocytes by interacting with a ‘low‐affinity’ phosphodiesterase 4 conformer , 1997, British journal of pharmacology.

[5]  M. Conti,et al.  Characterization of an intronic promoter of a cyclic adenosine 3',5'-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility. , 1997, Molecular endocrinology.

[6]  J. Souness,et al.  Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. , 1997, Cellular signalling.

[7]  P. Peachell,et al.  Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function , 1997, British journal of pharmacology.

[8]  S. Holgate,et al.  The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. , 1997, The European respiratory journal.

[9]  A. Dubois,et al.  Inhibition of PAF-induced expression of CD11b and shedding of L-selectin on human neutrophils and eosinophils by the type IV selective PDE inhibitor, rolipram. , 1997, The European respiratory journal.

[10]  A. Kagey‐Sobotka,et al.  Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen-specific human T lymphocyte clones. , 1997, Biochemical pharmacology.

[11]  B. Sanwal,et al.  Recombinant expression of a type IV, cAMP-specific phosphodiesterase: characterization and structure-function studies of deletion mutants. , 1997, Biochemistry.

[12]  R. Owens,et al.  PDE 4 inhibitors: the use of molecular cloning in the design and development of novel drugs , 1997 .

[13]  W. Rocque,et al.  Detailed characterization of a purified type 4 phosphodiesterase, HSPDE4B2B: differentiation of high- and low-affinity (R)-rolipram binding. , 1997, Protein expression and purification.

[14]  J. Ellis,et al.  Role of soluble guanylyl cyclase in the relaxations to a nitric oxide donor and to nonadrenergic nerve stimulation in guinea pig trachea and human bronchus. , 1997, The Journal of pharmacology and experimental therapeutics.

[15]  E. Pettipher,et al.  The Phosphodiesterase Type 4 (PDE4) Inhibitor CP-80,633 Elevates Plasma Cyclic AMP Levels and Decreases Tumor Necrosis Factor-α (TNFα) Production in Mice: Effect of Adrenalectomy , 1997 .

[16]  H. Danahay,et al.  Effects of inhibitors of phosphodiesterase, on antigen‐induced bronchial hyperreactivity in conscious sensitized guinea‐pigs and airway leukocyte infiltration , 1997, British journal of pharmacology.

[17]  A. Kagey‐Sobotka,et al.  Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. , 1997, The Journal of allergy and clinical immunology.

[18]  D. Underwood,et al.  The influence of endogenous catecholamines on the inhibitory effects of rolipram against early- and late-phase response to antigen in the guinea pig. , 1997, The Journal of pharmacology and experimental therapeutics.

[19]  M. Houslay,et al.  Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. , 1997, The Biochemical journal.

[20]  M. Conti,et al.  Role of multiple cAMP-specific phosphodiesterase variants. , 1996, Biochemical Society transactions.

[21]  C. Page,et al.  The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti‐asthma drugs on inflammatory cell activation , 1996, British journal of pharmacology.

[22]  M. Houslay.  The N-terminal alternately spliced regions of PDE4A cAMP-specific phosphodiesterases determine intracellular targeting and regulation of catalytic activity. , 1996, Biochemical Society transactions.

[23]  S Jacobitz,et al.  Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. , 1996, Molecular pharmacology.

[24]  M. Giembycz.  Phosphodiesterase 4 and tolerance to β2-adrenoceptor agonists in asthma , 1996 .

[25]  J. Cheng,et al.  In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633. , 1996, The Journal of pharmacology and experimental therapeutics.

[26]  P. Barnes,et al.  Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors. , 1996, The Biochemical journal.

[27]  M. Houslay,et al.  The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5). , 1996, The Biochemical journal.

[28]  M. Teixeira,et al.  Effects of agents which elevate cyclic AMP on guinea‐pig eosinophil homotypic aggregation , 1996, British journal of pharmacology.

[29]  J. Fozard,et al.  Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. , 1996, TIPS - Trends in Pharmacological Sciences.

[30]  P. Barnes,et al.  Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T‐lymphocytes: role in regulating proliferation and the biosynthesis of interleukin‐2 , 1996, British journal of pharmacology.

[31]  A. Hatzelmann,et al.  Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects , 1996, British journal of pharmacology.

[32]  C. Page,et al.  Effect of the glucocorticosteroid budesonide and a novel phosphodiesterase type 4 inhibitor CDP840 on antigen‐induced airway responses in neonatally immunised rabbits , 1996, British journal of pharmacology.

[33]  M. Holbrook,et al.  Inhibition of bronchospasm and ozone‐induced airway hyperresponsiveness in the guinea‐pig by CDP840, a novel phosphodiesterase type 4 inhibitor , 1996, British journal of pharmacology.

[34]  R. Owens,et al.  The inhibition of antigen‐induced eosinophilia and bronchoconstriction by CDP840, a novel stereo‐selective inhibitor of phosphodiesterase type 4 , 1996, British journal of pharmacology.

[35]  J. Karlsson,et al.  Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a ‘low‐affinity’ phosphodiesterase 4 conformer , 1996, British journal of pharmacology.

[36]  S. Christensen,et al.  Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding. , 1996, Biochemical pharmacology.

[37]  M. Conti,et al.  Identification of cyclic AMP‐phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells , 1996, FEBS letters.

[38]  C. Page,et al.  Effects of theophylline and rolipram on antigen‐induced airway responses in neonatally immunized rabbits , 1996, British journal of pharmacology.

[39]  P. Barnes,et al.  Paradoxical facilitation of acetylcholine release from parasympathetic nerves innervating guinea‐pig trachea by isoprenaline , 1996, British journal of pharmacology.

[40]  T. Greten,et al.  Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-alpha synthesis. , 1996, European journal of pharmacology.

[41]  R. Townley,et al.  Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. , 1996, Immunopharmacology.

[42]  N. Suttorp,et al.  Role of nitric oxide and phosphodiesterase isoenzyme II for reduction of endothelial hyperpermeability. , 1996, The American journal of physiology.

[43]  M. Mclaughlin,et al.  Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B. , 1996, The Journal of pharmacology and experimental therapeutics.

[44]  A. Marfat,et al.  Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. , 1996, Journal of medicinal chemistry.

[45]  M. Conti,et al.  Phosphorylation and Activation of a cAMP-specific Phosphodiesterase by the cAMP-dependent Protein Kinase , 1995, The Journal of Biological Chemistry.

[46]  C. Schudt,et al.  2 – Analysis of PDE Isoenzyme Profiles in Cells and Tissues by Pharmacological Methods , 1996 .

[47]  K. Ferguson,et al.  1 – Identification and Quantification of PDE Isoenzymes and Subtypes by Molecular Biological Methods , 1996 .

[48]  M. Kotlikoff,et al.  Molecular mechanisms of beta-adrenergic relaxation of airway smooth muscle. , 1996, Annual review of physiology.

[49]  J. Souness,et al.  Isoprenaline induction of cAMP-phosphodiesterase in guinea-pig macrophages occurs in the presence, but not in the absence, of the phosphodiesterase type IV inhibitor rolipram. , 1995, Biochemical pharmacology.

[50]  M. Drumm,et al.  CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells. , 1995, American journal of respiratory cell and molecular biology.

[51]  A. Kagey‐Sobotka,et al.  Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral blood mononuclear cells. , 1995, American journal of respiratory cell and molecular biology.

[52]  C. Page,et al.  Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis , 1995, British journal of pharmacology.

[53]  R J Heaslip,et al.  Emetic, central nervous system, and pulmonary activities of rolipram in the dog. , 1995, European journal of pharmacology.

[54]  G. Strassmann,et al.  Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages. , 1995, Journal of immunology.

[55]  D. E. Howell,et al.  Inhibition of lipopolysaccharide-induced pulmonary edema by isozyme-selective phosphodiesterase inhibitors in guinea pigs. , 1995, The Journal of pharmacology and experimental therapeutics.

[56]  F. Dallegri,et al.  Tumour necrosis factor alpha‐induced oxidative burst in neutrophils adherent to fibronectin: effects of cyclic AMP‐elevating agents , 1995, British journal of haematology.

[57]  V. Lagente,et al.  Involvement of cyclic AMP in the effects of phosphodiesterase IV inhibitors on arachidonate release from mononuclear cells. , 1995, European journal of pharmacology.

[58]  H. Sarau,et al.  Salbutamol Up-regulates PDE4 Activity and Induces a Heterologous Desensitization of U937 Cells to Prostaglandin E2 , 1995, The Journal of Biological Chemistry.

[59]  M. Conti,et al.  Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. , 1995, Molecular pharmacology.

[60]  P. Barnes,et al.  Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. , 1995, Molecular pharmacology.

[61]  J. Beavo,et al.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. , 1995, Physiological reviews.

[62]  M. Houslay,et al.  Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family. , 1995, The Biochemical journal.

[63]  E. Degerman,et al.  Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. , 1995, Archives of biochemistry and biophysics.

[64]  C. Penland,et al.  Beta-adrenergic regulation of Cl- and HCO3- secretion by Clara cells. , 1995, American journal of respiratory cell and molecular biology.

[65]  A. Moore,et al.  The role of cAMP regulation in controlling inflammation , 1995, Clinical and experimental immunology.

[66]  F. Dallegri,et al.  Cyclic AMP‐elevating agents down‐regulate the oxidative burst induced by granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) in adherent neutrophils , 1995, Clinical and experimental immunology.

[67]  A. Hatzelmann,et al.  PDE isoenzymes as targets for anti-asthma drugs. , 1995, The European respiratory journal.

[68]  R. Djukanović,et al.  Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages , 1995, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[69]  R. Djukanović,et al.  Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes , 1995, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[70]  J. Nadel,et al.  Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils. , 1995, Cellular signalling.

[71]  J. Hanifin,et al.  Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. , 1995, The Journal of investigative dermatology.

[72]  T. Greten,et al.  The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide. , 1995, International journal of immunopharmacology.

[73]  G. Sybrecht,et al.  Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction. , 1995, Respiratory medicine.

[74]  A. Stewart,et al.  Salbutamol inhibits the proliferation of human airway smooth muscle cells grown in culture: relationship to elevated cAMP levels. , 1995, Biochemical pharmacology.

[75]  M. Houslay,et al.  Molecular cloning of a novel splice variant of human type IVA (PDE-IVA) cyclic AMP phosphodiesterase and localization of the gene to the p13.2-q12 region of human chromosome 19 , 1995 .

[76]  M. Conti,et al.  Recent progress in understanding the hormonal regulation of phosphodiesterases. , 1995, Endocrine reviews.

[77]  M. Pruniaux,et al.  Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors. , 1995, American journal of respiratory and critical care medicine.

[78]  J. Lenhard,et al.  Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. , 1995, Molecular pharmacology.

[79]  M. Olszewski,et al.  Beta 2-adrenoceptor activation augments acetylcholine release from tracheal parasympathetic nerves. , 1995, The American journal of physiology.

[80]  S. Christensen,et al.  Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. , 1995, The Journal of pharmacology and experimental therapeutics.

[81]  M. Ashton,et al.  Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP‐specific phosphodiesterase: comparison with rolipram , 1995, British journal of pharmacology.

[82]  S. Christensen,et al.  The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. , 1995, The Journal of pharmacology and experimental therapeutics.

[83]  L. Jenkins,et al.  Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats. , 1995, Pulmonary pharmacology.

[84]  B. Mayer,et al.  SH3 Domains: Minding your p's and q's , 1995, Current Biology.

[85]  J. Beattie,et al.  Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum. , 1995, The Biochemical journal.

[86]  D. Yarnall,et al.  Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. , 1995, The Journal of pharmacology and experimental therapeutics.

[87]  M. Yacoub,et al.  Evidence for the involvement of cGMP in neural bronchodilator responses in humal trachea. , 1995, The Journal of physiology.

[88]  J. Ellis,et al.  Modulation of relaxant responses evoked by a nitric oxide donor and by nonadrenergic, noncholinergic stimulation by isozyme-selective phosphodiesterase inhibitors in guinea pig trachea. , 1995, Journal of Pharmacology and Experimental Therapeutics.

[89]  R. Santing,et al.  Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs. , 1995, European journal of pharmacology.

[90]  C. Page,et al.  The effect of selective phosphodiesterase inhibitors in comparison with other anti-asthma drugs on allergen-induced eosinophilia in guinea-pig airways. , 1995, Pulmonary pharmacology.

[91]  H. Takeda,et al.  Studies on anti-allergic action of AH 21-132, a novel isozyme-selective phosphodiesterase inhibitor in airways. , 1995, Japanese journal of pharmacology.

[92]  A. Hatzelmann,et al.  Differential effects of non‐selective and selective phosphodiesterase inhibitors on human eosinophil functions , 1995, British journal of pharmacology.

[93]  M. Niwa,et al.  Heterogeneity of circulating and exudated polymorphonuclear leukocytes in superoxide-generating response to cyclic AMP and cyclic AMP-elevating agents. Investigation of the underlying mechanism. , 1995, Biochemical pharmacology.

[94]  H. Lübbert,et al.  Molecular cloning and functional expression in yeast of a human cAMP‐specific phosphodiesterase subtype (PDE IV‐C) , 1995, FEBS letters.

[95]  K. Ikai,et al.  Elevated cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from children with atopic dermatitis , 1995, The British journal of dermatology.

[96]  C. Page,et al.  Acute versus chronic administration of phosphodiesterase inhibitors on allergen‐induced pulmonary cell influx in sensitized guinea‐pigs , 1995, British journal of pharmacology.

[97]  S. Endres,et al.  Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids , 1995, European journal of immunology.

[98]  T. Lincoln,et al.  cGMP signaling through cAMP- and cGMP-dependent protein kinases. , 1995, Advances in pharmacology.

[99]  C. Derian,et al.  Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. , 1995, Journal of immunology.

[100]  P. Barnes,et al.  Nitric oxide as a neurotransmitter in human airways. , 1995, Archives internationales de pharmacodynamie et de therapie.

[101]  M. Fujimura,et al.  Bronchodilator and bronchoprotective effects of cilostazol in humans in vivo. , 1995, American journal of respiratory and critical care medicine.

[102]  K. Rabe,et al.  Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. , 1994, The Journal of pharmacology and experimental therapeutics.

[103]  C. Battram,et al.  Anti‐inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor , 1994, British journal of pharmacology.

[104]  J. Beattie,et al.  Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions. , 1994, The Biochemical journal.

[105]  D. Underwood,et al.  Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma. , 1994, Environmental health perspectives.

[106]  S. Meeker,et al.  Inhibition of neurally mediated nonadrenergic, noncholinergic contractions of guinea pig bronchus by isozyme-selective phosphodiesterase inhibitors. , 1994, The Journal of pharmacology and experimental therapeutics.

[107]  B. Undem,et al.  Potentiation of nonadrenergic noncholinergic relaxation of human isolated bronchus by selective inhibitors of phosphodiesterase isozymes. , 1994, American journal of respiratory and critical care medicine.

[108]  G. Bolger,et al.  Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. , 1994, Cellular signalling.

[109]  A. Kagey‐Sobotka,et al.  Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. , 1994, Journal of immunology.

[110]  E. F. Smith,et al.  Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. , 1994, International journal of immunopharmacology.

[111]  T. Torphy,et al.  Beta-adrenoceptors, cAMP and airway smooth muscle relaxation: challenges to the dogma. , 1994, Trends in pharmacological sciences.

[112]  J. Beavo,et al.  Multiple cyclic nucleotide phosphodiesterases. , 1994, Molecular pharmacology.

[113]  H. Lübbert,et al.  Expression and regulation of human and rat phosphodiesterase type IV isogenes , 1994, FEBS letters.

[114]  M. Conti,et al.  The ratPDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase. , 1994, The Journal of biological chemistry.

[115]  D. Underwood,et al.  Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. , 1994, The Journal of pharmacology and experimental therapeutics.

[116]  B. Fischer,et al.  Interactions between Respiratory Epithelial Cells and Cytokines: Relationships to Lung Inflammation , 1994, Annals of the New York Academy of Sciences.

[117]  C. Andresen,et al.  Effects of rolipram on responses to acute and chronic antigen exposure in monkeys. , 1994, American journal of respiratory and critical care medicine.

[118]  V. Lagente,et al.  Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung. , 1994, European journal of pharmacology.

[119]  N. Turner,et al.  Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in the anaesthetized guinea‐pig , 1994, British journal of pharmacology.

[120]  M. Conti,et al.  The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. , 1994, The Journal of biological chemistry.

[121]  U. Francke,et al.  Chromosome localizations of genes for five cAMP-specific phosphodiesterases in man and mouse , 1994, Somatic cell and molecular genetics.

[122]  S. Moestrup,et al.  Receptor‐mediated endocytosis of plasminogen activators and activator/inhibitor complexes , 1994, FEBS letters.

[123]  R J Heaslip,et al.  Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641. , 1994, The Journal of pharmacology and experimental therapeutics.

[124]  A. Stewart,et al.  Inhibition by salbutamol of the proliferation of human airway smooth muscle cells grown in culture , 1994, British journal of pharmacology.

[125]  C. Nicholson,et al.  Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes--their potential utility in the therapy of asthma. , 1994, Pulmonary pharmacology.

[126]  I. Hall,et al.  Beta-adrenergic agonists regulate KCa channels in airway smooth muscle by cAMP-dependent and -independent mechanisms. , 1994, The Journal of clinical investigation.

[127]  J. Karlsson,et al.  Effects of isoenzyme-selective inhibitors of cyclic nucleotide phosphodiesterase on microvascular leak in guinea pig airways in vivo. , 1993, The Journal of pharmacology and experimental therapeutics.

[128]  J. Cortijo,et al.  Rolipram inhibits airway microvascular leakage induced by platelet‐activating factor, histamine and bradykinin in guinea‐pigs , 1993, The Journal of pharmacy and pharmacology.

[129]  P. Paré,et al.  Small airways dimensions in asthma and in chronic obstructive pulmonary disease. , 1993, The American review of respiratory disease.

[130]  D. Cockcroft,et al.  Regular inhaled salbutamol and airway responsiveness to allergen , 1993, The Lancet.

[131]  M. Wigler,et al.  A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs , 1993, Molecular and cellular biology.

[132]  K. Jarnagin,et al.  The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family. , 1993, Gene.

[133]  B. Undem,et al.  Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. , 1993, The Journal of pharmacology and experimental therapeutics.

[134]  A. Fonteh,et al.  Influence of isoproterenol and phosphodiesterase inhibitors on platelet-activating factor biosynthesis in the human neutrophil. , 1993, Journal of immunology.

[135]  H. Kase,et al.  A new cyclic nucleotide phosphodiesterase isozyme expressed in the T-lymphocyte cell lines. , 1993, Biochemical and biophysical research communications.

[136]  P. Kalinski,et al.  Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. , 1993, Journal of immunology.

[137]  M. Wigler,et al.  Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. , 1993, The Journal of biological chemistry.

[138]  M. Houslay,et al.  Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram. , 1993, The Biochemical journal.

[139]  J. Pober,et al.  Elevated cyclic AMP inhibits endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1. , 1993, Journal of immunology.

[140]  B. Undem,et al.  Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. , 1993, The Journal of pharmacology and experimental therapeutics.

[141]  J. Hanifin,et al.  Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. , 1993, The Journal of investigative dermatology.

[142]  H. Magnussen,et al.  Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. , 1993, The American journal of physiology.

[143]  S. Endres,et al.  The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. , 1993, International journal of immunopharmacology.

[144]  M. Mclaughlin,et al.  A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA. , 1993, The Journal of biological chemistry.

[145]  E. Wheeldon,et al.  Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition. , 1993, Circulatory shock.

[146]  J. Cortijo,et al.  Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus , 1993, British journal of pharmacology.

[147]  B. Sickels,et al.  Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs. , 1993, The Journal of pharmacology and experimental therapeutics.

[148]  F. Schade,et al.  The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. , 1993, European journal of pharmacology.

[149]  J. Hanifin,et al.  Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes. , 1993, The Journal of laboratory and clinical medicine.

[150]  G. P. Livi,et al.  Biochemical characteristics and cellular regulation of phosphodiesterase IV. , 1993, Agents and actions. Supplements.

[151]  H. Kase,et al.  New bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones. , 1992, Journal of medicinal chemistry.

[152]  B. Undem,et al.  Inhibition by L-NG-nitro-L-arginine of nonadrenergic-noncholinergic-mediated relaxations of human isolated central and peripheral airway. , 1992, The American review of respiratory disease.

[153]  T. Torphy,et al.  Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. , 1992, The Journal of pharmacology and experimental therapeutics.

[154]  J. R. Carpenter,et al.  Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AH 21-132 in healthy volunteers during a methacholine challenge test. , 1992, British journal of clinical pharmacology.

[155]  M. Kotlikoff,et al.  Stimulatory and inhibitory regulation of calcium-activated potassium channels by guanine nucleotide-binding proteins. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[156]  M. Karin,et al.  Control of transcription factors by signal transduction pathways: the beginning of the end. , 1992, Trends in biochemical sciences.

[157]  A. Knowles,et al.  The effect of SK&F 95654, a novel phosphodiesterase inhibitor, on cardiovascular, respiratory and platelet function , 1992, British journal of pharmacology.

[158]  G. Hassall,et al.  Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. , 1992, Biochemical pharmacology.

[159]  V. Steinijans,et al.  Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. , 1992, The European respiratory journal.

[160]  Alison J. Philpott,et al.  Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors , 1992, British journal of pharmacology.

[161]  W. Schunack,et al.  Inhibition of IgE-mediated histamine release from human peripheral leukocytes by selective phosphodiesterase inhibitors. , 1992, Agents and actions.

[162]  M. Giembycz.  Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? , 1992, Biochemical pharmacology.

[163]  F. Paliogianni,et al.  Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R alpha gene expression at multiple levels. , 1992, Journal of immunology.

[164]  L. Lichtenstein,et al.  Preliminary identification and role of phosphodiesterase isozymes in human basophils. , 1992, Journal of immunology.

[165]  N. Pyne,et al.  The catalytic subunit of protein kinase A triggers activation of the type V cyclic GMP-specific phosphodiesterase from guinea-pig lung. , 1992, The Biochemical journal.

[166]  K. Sherry,et al.  Pharmacology, mechanisms of action and uses of selective phosphodiesterase inhibitors. , 1992, British journal of anaesthesia.

[167]  Pierre Ernst,et al.  The Use of β-Agonists and the Risk of Death and near Death from Asthma , 1992 .

[168]  M. Grunstein,et al.  Assessment of signal transduction mechanisms regulating airway smooth muscle contractility. , 1992, The American journal of physiology.

[169]  R. Louis,et al.  LY 186655, a phosphodiesterase inhibitor, inhibits histamine release from human basophils, lung and skin fragments. , 1992, International journal of immunopharmacology.

[170]  M. Mclaughlin,et al.  Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. , 1992, The Journal of biological chemistry.

[171]  M. Yacoub,et al.  Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans. , 1992, European journal of pharmacology.

[172]  K. Chung,et al.  Questions about inhaled β2-adrenoceptor agonists in asthma , 1992 .

[173]  G. P. Livi,et al.  Therapeutic potential of isozyme-selective phosphodiesterase inhibitors in the treatment of asthma. , 1992, Advances in second messenger and phosphoprotein research.

[174]  A. Taylor,et al.  Reversal of increased microvascular permeability associated with ischemia-reperfusion: role of cAMP. , 1992, Journal of applied physiology.

[175]  M. Giembycz,et al.  Putative substrates for cyclic nucleotide-dependent protein kinases and the control of airway smooth muscle tone. , 1991, Journal of autonomic pharmacology.

[176]  R. L. Roper,et al.  A new view of prostaglandin E regulation of the immune response. , 1991, Immunology today.

[177]  F. Orson,et al.  Cyclic AMP-mediated modulation of immunoglobulin production in B cells by prostaglandin E1. , 1991, Cellular immunology.

[178]  M. Conti,et al.  Properties and hormonal regulation of two structurally related cAMP phosphodiesterases from the rat Sertoli cell. , 1991, The Journal of biological chemistry.

[179]  T. Torphy,et al.  Relationship between cyclic guanosine monophosphate accumulation and relaxation of canine trachealis induced by nitrovasodilators. , 1991, The Journal of pharmacology and experimental therapeutics.

[180]  R. Martin,et al.  Regular inhaled beta-adrenergic agonists in the treatment of bronchial asthma: beneficial or detrimental? , 1991, The American review of respiratory disease.

[181]  D. Blanchard,et al.  Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. , 1991, Biochemical pharmacology.

[182]  N. Turner,et al.  Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation. , 1991, Biochemical pharmacology.

[183]  B. Undem,et al.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. , 1991, Thorax.

[184]  M. Auffredou,et al.  Modulation of IL-2- and IL-4-dependent human B cell proliferation by cyclic AMP. , 1991, Journal of immunology.

[185]  K. Rabe,et al.  Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan‐stimulated respiratory burst by ‘type IV’‐selective PDE inhibitors , 1991, British journal of pharmacology.

[186]  W. Thompson,et al.  Phosphodiesterase II, the cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cyclic AMP metabolism in PC12 cells. , 1991, Molecular pharmacology.

[187]  R. Heaslip,et al.  Bronchial vs. cardiovascular activities of selective phosphodiesterase inhibitors in the anesthetized beta-blocked dog. , 1991, The Journal of pharmacology and experimental therapeutics.

[188]  A. Schmitt‐Verhulst,et al.  Cyclic AMP synergy with Ca2+ for production of IFN-gamma by a cytolytic T cell clone is post-transcriptional. , 1991, Journal of immunology.

[189]  C. Page.  One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by β2-agonists , 1991, The Lancet.

[190]  T. Torphy,et al.  Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis. , 1991, Molecular pharmacology.

[191]  J. Tamaoki,et al.  Atrial natriuretic factor inhibits ciliary motility in cultured rabbit tracheal epithelium. , 1991, The American journal of physiology.

[192]  D. Crankshaw,et al.  Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle. , 1991, European journal of pharmacology.

[193]  J. Beavo,et al.  High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. , 1991, The Journal of biological chemistry.

[194]  W. Thompson.  Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. , 1991, Pharmacology & therapeutics.

[195]  T. Torphy,et al.  Potential use of selective phosphodiesterase inhibitors in the treatment of asthma. , 1991, Agents and actions. Supplements.

[196]  N. Saccomano,et al.  Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkyloxy)-4-methoxyphenyl]-2-imidazolidinones. , 1991, Journal of medicinal chemistry.

[197]  E. Degerman,et al.  Molecular mechanisms involved in the antilipolytic action of insulin: phosphorylation and activation of a particulate adipocyte cAMP phosphodiesterase. , 1991, Advances in experimental medicine and biology.

[198]  C. Print,et al.  Regular inhaled beta-agonist treatment in bronchial asthma , 1990, The Lancet.

[199]  C. Lugnier,et al.  Involvement of Rolipram-Sensitive Cyclic AMP Phosphodiesterase in the Regulation of Cardiac Contraction , 1990, Journal of cardiovascular pharmacology.

[200]  R. Vestal,et al.  Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. , 1990, The Journal of allergy and clinical immunology.

[201]  J. Corbin,et al.  Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. , 1990, The Journal of biological chemistry.

[202]  J. Corbin,et al.  Substrate- and kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP. , 1990, The Journal of biological chemistry.

[203]  C. Wright,et al.  Differential inhibition of human neutrophil functions. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase. , 1990, Biochemical pharmacology.

[204]  E. Gelfand,et al.  Increased cyclic adenosine monophosphate levels block progression but not initiation of human T cell proliferation. , 1990, Journal of immunology.

[205]  Taylor,et al.  Cloning and expression of cDNA for a human low-Km, rolipram-sensitive cyclic AMP phosphodiesterase , 1990, Molecular and cellular biology.

[206]  R. Haslam,et al.  Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. , 1990, Molecular pharmacology.

[207]  N. Pearce,et al.  Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. , 1990, Thorax.

[208]  R. Howell,et al.  Mechanism for the emetic side effect of xanthine bronchodilators. , 1990, Life sciences.

[209]  M. Conti,et al.  The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[210]  M. Connell,et al.  Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig. , 1989, The Journal of pharmacology and experimental therapeutics.

[211]  S. Robicsek,et al.  High pressure liquid chromatography of cyclic nucleotide phosphodiesterase from purified human T-lymphocytes. , 1989, Biochemical and biophysical research communications.

[212]  E. Leonard,et al.  Interactions of formylmethionyl‐leucyl‐phenylalanine, adenosine, and phosphodiesterase inhibitors in human monocytes Effects on superoxide release, inositol phosphates and cAMP , 1989, FEBS letters.

[213]  T. Soderling,et al.  Regulation of Ca2+/calmodulin-dependent cyclic nucleotide phosphodiesterase by the autophosphorylated form of Ca2+/calmodulin-dependent protein kinase II. , 1989, The Journal of biological chemistry.

[214]  N. Pearce,et al.  PRESCRIBED FENOTEROL AND DEATH FROM ASTHMA IN NEW ZEALAND, 1981-83; CASE-CONTROL STUDY , 1989, The Lancet.

[215]  J. Weil,et al.  Role of cyclic adenosine monophosphate in the induction of endothelial barrier properties , 1989, Journal of cellular physiology.

[216]  M. Kondo,et al.  Effect of cAMP on ciliary function in rabbit tracheal epithelial cells. , 1989, Journal of applied physiology.

[217]  M. Wood,et al.  Long-term oral therapy of congestive heart failure with phosphodiesterase inhibitors. , 1989, The American journal of the medical sciences.

[218]  J. Jauniaux,et al.  The cyclic AMP-mediated stimulation of cell proliferation. , 1989, Trends in biochemical sciences.

[219]  G. Naccarelli,et al.  Electrophysiology of phosphodiesterase inhibitors. , 1989, The American journal of cardiology.

[220]  W. Hood.  Controlled and uncontrolled studies of phosphodiesterase III inhibitors in contemporary cardiovascular medicine. , 1989, The American journal of cardiology.

[221]  J. Hanifin.  Pharmacological abnormalities in atopic dermatitis , 1989, Allergy.

[222]  F. Orson,et al.  Modulation of a human lymphoblastoid B cell line by cyclic AMP. Ig secretion and phosphatidylcholine metabolism. , 1988, Journal of immunology.

[223]  T. Torphy,et al.  Inhibition of the low km cyclic AMP phosphodiesterase in intact canine trachealis by SK&F 94836: mechanical and biochemical responses. , 1988, The Journal of pharmacology and experimental therapeutics.

[224]  K. Smith,et al.  cAMP antagonizes interleukin 2-promoted T-cell cycle progression at a discrete point in early G1. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[225]  N. Strominger,et al.  Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides. , 1988, Journal of neurophysiology.

[226]  G. Kammer.  The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. , 1988, Immunology today.

[227]  R. Fuller,et al.  Human alveolar macrophage activation: inhibition by forskolin but not beta-adrenoceptor stimulation or phosphodiesterase inhibition. , 1988, Pulmonary pharmacology.

[228]  M. Welsh.  Effect of phorbol ester and calcium ionophore on chloride secretion in canine tracheal epithelium. , 1987, The American journal of physiology.

[229]  B. Ferruà,et al.  Regulation of interleukin 2 synthesis by cAMP in human T cells. , 1987, Journal of immunology.

[230]  M. Zanetti,et al.  Cyclic AMP-dependent regulation of lipid mediators in white cells. A unifying concept for explaining the efficacy of theophylline in asthma. , 1987, The American review of respiratory disease.

[231]  C. Mélot,et al.  Reduction in pulmonary hypertension and in airway resistances by enoximone (MDL 17,043) in decompensated COPD. , 1987, Chest.

[232]  A. Newman,et al.  Purification of the putative hormone-sensitive cyclic AMP phosphodiesterase from rat adipose tissue using a derivative of cilostamide as a novel affinity ligand. , 1987, The Journal of biological chemistry.

[233]  T. Torphy,et al.  Regulation of cAMP content and cAMP-dependent protein kinase activity in airway smooth muscle. , 1987, Progress in clinical and biological research.

[234]  J. Beavo,et al.  Identification of a conserved domain among cyclic nucleotide phosphodiesterases from diverse species. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[235]  S. Holgate,et al.  Relationships between adenosine, cyclic nucleotides, and xanthines in asthma. , 1986, The Journal of allergy and clinical immunology.

[236]  C. Persson.  Overview of effects of theophylline. , 1986, The Journal of allergy and clinical immunology.

[237]  J. Hanifin,et al.  Monocyte localization of elevated cAMP phosphodiesterase activity in atopic dermatitis. , 1986, The Journal of investigative dermatology.

[238]  M. Brezinski,et al.  Stereospecific binding of the antidepressant rolipram to brain protein structures. , 1986, European journal of pharmacology.

[239]  J. Beavo,et al.  Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. , 1986, Molecular pharmacology.

[240]  T. K. Harden,et al.  Identification of the phosphodiesterase regulated by muscarinic cholinergic receptors of 1321N1 human astrocytoma cells. , 1986, Molecular pharmacology.

[241]  S. Nourshargh,et al.  Inhibition of human neutrophil degranulation by forskolin in the presence of phosphodiesterase inhibitors. , 1986, European journal of pharmacology.

[242]  E. Braunwald,et al.  New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2. , 1986, The New England journal of medicine.

[243]  J. Warner,et al.  The effect of zaprinast (M&B 22,948, an orally absorbed mast cell stabilizer) on exercise-induced asthma in children. , 1986, British journal of diseases of the chest.

[244]  J. Dumont,et al.  A mechanism in the control of intracellular cAMP level: the activation of a calmodulin-sensitive phosphodiesterase by a rise of intracellular free calcium , 1985, Molecular and Cellular Endocrinology.

[245]  J. Hanifin,et al.  Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro. , 1985, The Journal of investigative dermatology.

[246]  R. Sharma,et al.  Differential regulation of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isoenzymes by cyclic AMP-dependent protein kinase and calmodulin-dependent phosphatase. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[247]  R. Horowski,et al.  Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports , 1985 .

[248]  J. Hanifin,et al.  Increased leukocyte sensitivity to phosphodiesterase inhibitors in atopic dermatitis: tachyphylaxis after theophylline therapy. , 1984, The Journal of allergy and clinical immunology.

[249]  H. Hidaka,et al.  Selective inhibitors of three forms of cyclic nucleotide phosphodiesterases , 1984 .

[250]  I. Strannegård,et al.  Effect of cyclic AMP-elevating agents on human spontaneous IgE synthesis in vitro. , 1984, International archives of allergy and applied immunology.

[251]  J. Hanifin,et al.  Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. , 1983, The Journal of allergy and clinical immunology.

[252]  D. Geddes,et al.  Inhibition of exercise-induced asthma by an orally absorbed mast cell stabilizer (M & B 22,948). , 1983, British journal of diseases of the chest.

[253]  J. Hanifin,et al.  Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. , 1982, The Journal of allergy and clinical immunology.

[254]  J. Hanifin,et al.  Functional desensitization due to stimulation of cyclic AMP-phosphodiesterase in human mononuclear leukocytes. , 1982, Journal of cyclic nucleotide research.

[255]  G. Pauli,et al.  EFFECTS OF CYCLIC AMP‐ AND CYCLIC GMP‐PHOSPHODIESTERASE INHIBITORS ON IMMUNOLOGICAL RELEASE OF HISTAMINE AND ON LUNG CONTRACTION , 1981, British journal of pharmacology.

[256]  J. N. Wells,et al.  Inhibition of separated forms of cyclic nucleotide phosphodiesterase from pig coronary arteries by 1,3-disubstituted and 1,3,8-trisubstituted xanthines. , 1981, Journal of medicinal chemistry.

[257]  E. Krebs,et al.  Phosphorylation-dephosphorylation of enzymes. , 1979, Annual review of biochemistry.

[258]  A. L. Goldman,et al.  INHIBITION OF HUMAN PULMONARY PHOSPHODIESTERASE ACTIVITY BY THERAPEUTIC LEVELS OF THEOPHYLLINE , 1978, Clinical and experimental pharmacology & physiology.

[259]  W. Busse.  Decreased granulocyte response to isoproterenol in asthma during upper respiratory infections. , 2015, The American review of respiratory disease.

[260]  J. Beland,et al.  Nonadrenergic inhibitory nervous system in human airways. , 1976, Journal of applied physiology.

[261]  E. Hersh,et al.  Cyclic adenosine 3':5'-monophosphate phosphodiesterase. Distinct forms in human lymphocytes and monocytes. , 1976, The Journal of biological chemistry.

[262]  B. Weiss,et al.  Mechanism by which psychotropic drugs inhibit adenosine cyclic 3',5'-monophosphate phosphodiesterase of brain. , 1976, Molecular pharmacology.

[263]  R. A. Johnson,et al.  The role of cyclic nucleotides in the cell cycle. , 1976, Advances in cyclic nucleotide research.

[264]  G. S. Johnson,et al.  Role of cyclic nucleotides in growth control. , 1975, Annual review of biochemistry.

[265]  H. Bourne,et al.  Modulation of Inflammation and Immunity by Cyclic AMP , 1974 .

[266]  J. W. Smith,et al.  Alterations in cyclic adenosine monophosphate metabolism in human bronchial asthma. I. Leukocyte responsiveness to -adrenergic agents. , 1973, The Journal of clinical investigation.

[267]  M. M. Appleman,et al.  Cyclic nucleotide phosphodiesterases. , 1982 .

[268]  M. M. Appleman,et al.  Characterization of cyclic nucleotide phosphodiesterases of rat tissues. , 1971, The Journal of biological chemistry.

[269]  J. Beavo,et al.  Hydrolysis of cyclic guanosine and adenosine 3',5'-monophosphates by rat and bovine tissues. , 1970, The Journal of biological chemistry.

[270]  J. Anderson,et al.  A comparison of the quantitative anatomy of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis, and in emphysema , 1969, Thorax.

[271]  E. Sutherland,et al.  Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. , 1958, The Journal of biological chemistry.